Physician profile
Dwight P Ligham
NPI 1669584686
$7,420.56
in general payments reported to CMS, 2019-2025
27 companies · $66.80 in 2025
The $66.80 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,806 · 2020: $447 · 2021: $456 · 2022: $3,277 · 2023: $204 · 2024: $164 · 2025: $66.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $2,537.41 | 2022-2023 | Intracept |
| Vertiflex, INC. | $1,642.68 | 2019 | |
| Abbott Laboratories | $1,604.26 | 2019-2025 | Proclaim, Eterna |
| Foundation Fusion Solutions, LLC | $537.58 | 2020-2024 | |
| Collegium Pharmaceutical, INC. | $230.99 | 2019-2020 | |
| Boston Scientific Corporation | $133.30 | 2020-2024 | Intracept |
| Mdd US Operations, LLC | $132.95 | 2019-2020 | |
| Spr Therapeutics, INC | $57.95 | 2024-2025 | Sprint Pns System |
| Nevro Corp. | $55.75 | 2019 | |
| Vertos Medical, INC. | $54.63 | 2021 | |
| Arbor Pharmaceuticals, INC. | $45.80 | 2019 | |
| Kaleo, INC. | $45.05 | 2019 | |
| Medtronic USA, INC. | $36.75 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $34.88 | 2019 | |
| Medtronic, INC. | $31.24 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $29.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.14 | 2019 | |
| Scilex Pharmaceuticals INC. | $26.54 | 2019 | |
| Assertio Therapeutics, INC. | $23.79 | 2019 | |
| Fidia Pharma USA INC. | $22.08 | 2019 | |
| Amgen INC. | $20.31 | 2019 | |
| Tersera Therapeutics LLC | $18.14 | 2019 | |
| Biodelivery Sciences International, INC. | $16.46 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.20 | 2019 | |
| Lilly USA, LLC | $13.92 | 2019 | |
| Shionogi INC | $13.56 | 2019 | |
| Saluda Medical Americas, INC. | $10.57 | 2023 | Evoke Scs |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dwight Ligham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.